The catecholaminergic–cholinergic balance hypothesis of bipolar disorder revisited
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Bipolar disorder is a unique illness characterized by fluctuations between mood states of depression and mania. Originally, an adrenergic-cholinergic balance hypothesis was postulated to underlie these different affective states. In this review, we update this hypothesis with recent findings from human and animal studies, suggesting that a catecholaminergic-cholinergic hypothesis may be more relevant. Evidence from neuroimaging studies, neuropharmacological interventions, and genetic associations support the notion that increased cholinergic functioning underlies depression, whereas increased activations of the catecholamines (dopamine and norepinephrine) underlie mania. Elevated functional acetylcholine during depression may affect both muscarinic and nicotinic acetylcholine receptors in a compensatory fashion. Increased functional dopamine and norepinephrine during mania on the other hand may affect receptor expression and functioning of dopamine reuptake transporters. Despite increasing evidence supporting this hypothesis, a relationship between these two neurotransmitter systems that could explain cycling between states of depression and mania is missing. Future studies should focus on the influence of environmental stimuli and genetic susceptibilities that may affect the catecholaminergic-cholinergic balance underlying cycling between the affective states. Overall, observations from recent studies add important data to this revised balance theory of bipolar disorder, renewing interest in this field of research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative
Merikangas, K. R., Jin, R., He, J.-P., Kessler, R. C., Lee, S., Sampson, N. A., Viana, M. C., Andrade, L. H., Hu, C., Karam, E. G., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.12 · Cited by 2,627 · cited 2×
“Introduction Bipolar disorder is a debilitating neuropsychiatric illness that affects approximately 1% of the global population (Merikangas et al., 2011).”
BackgroundCryan, J. F., Mombereau, C., & Vassout, A. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.009 · Cited by 1,674
Neurotransmitters and neuromodulators in the basal ganglia
Graybiel, A. M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90104-i · Cited by 1,576
Gold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
Smoking, smoking cessation, and major depression
Glassman, A. H. (1990) · JAMA · doi:10.1001/jama.1990.03450120058029 · Cited by 1,207
A cholinergic-adrenergic hypothesis of mania and depression
Janowsky, D., Davis, J., El-Yousef, M. K., & Sekerke, H. J. (1972) · The Lancet · doi:10.1016/s0140-6736(72)93021-8 · Cited by 1,134
Self-citationExcess Mortality in Bipolar and Unipolar Disorder in Sweden
Ösby, U., Brandt, L., Correia, N., Ekbom, A., & Sparén, P. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.844 · Cited by 1,120 · cited 2×
“, 2010), and the associated mortality rate from suicide attempts is high in this population (Osby et al., 2001).”
BackgroundForced swimming test in mice: A review of antidepressant activity
Petit-Demouliere, B., Chenu, F., & Bourin, M. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2048-7 · Cited by 1,003 · cited 1×
“The most commonly used assay to study antidepressant effects and depression is the measurement of immobility duration in the tail suspension test (Cryan et al., 2005) and forced swim test (Petit-Demouliere et al., 2005), which is interpreted as a measure of depression-like “behavioral despair”.”
MethodMania-like behavior induced by disruption of CLOCK
Roybal, K., Theobold, D., Graham, A., DiNieri, J. A., Russo, S. J., Krishnan, V., Chakravarty, S., Peevey, J., Oehrlein, N., Birnbaum, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609625104 · Cited by 803
Neurobiological similarities in depression and drug dependence: a self-medication hypothesis
Markou, A. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00113-9 · Cited by 767
Regulation of dopaminergic transmission and cocaine reward by the Clock gene
McClung, C. A., Sidiropoulou, K., Vitaterna, M., Takahashi, J. S., White, F. J., Cooper, D. C., & Nestler, E. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503584102 · Cited by 493 · cited 3×
“…rhythms, ↓ sleep, hyperactivity, ↑ reward sensitivity to cocaine, PPI deficits, hyperexploration, ↑ hedonia-like behavior, ↑ DA firing and release Mania-like McClung et al. 2005; Roybal et al. 2007; van Enkhuizen et al. 2013a; Spencer et al. 2012 Treatments Lithium ↓ stimulant-induced…”
BackgroundToward constructing an endophenotype strategy for bipolar disorders
Hasler, G., Drevets, W. C., Gould, T. D., Gottesman, I. I., & Manji, H. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.006 · Cited by 423
Mechanisms of dopamine transporter regulation in normal and disease states
Vaughan, R. A., & Foster, J. D. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.07.005 · Cited by 419 · cited 3×
“The mixed findings to date (Hahn and Blakely, 2007) and linkage of dopamine transporter with attention deficit disorder (Vaughan and Foster, 2013) and schizophrenia, indicates that future research is required to fully examine the role of these transporters in bipolar disorder.”
BackgroundFurey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417 · cited 2×
“Intravenously administered scopolamine rapidly attenuated symptoms of depression in both major depressive disorder and bipolar depressed patients (Furey and Drevets, 2006), a finding replicated in patients with major depressive disorder (Drevets and Furey, 2010; Furey et al., 2010) and bipolar…”
ResultDopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder
Berk, M., Dodd, S., Kauer‐Sant’Anna, M., Malhi, G. S., Bourin, M., Kapczinski, F., & Norman, T. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01058.x · Cited by 396
Mineur, Y. S., Obayemi, A., Wigestrand, M. B., Fote, G. M., Calarco, C. A., Li, A. M., & Picciotto, M. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219731110 · Cited by 375 · cited 2×
“Similar to rats and humans, physostigmine also induced depression- and anxiety-like behaviors in C57BL/6 mice also (Mineur et al., 2013) without affecting locomotion.”
BackgroundThe Flinders sensitive line rats: a genetic animal model of depression
Overstreet, D. H. (1993) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80230-1 · Cited by 369 · cited 1×
“Furthermore, this line exhibits depression-like behaviors including lower startle thresholds (Markou et al., 1994), fulfilling some criteria of face, construct, and predictive validities [see (Overstreet, 1993) for review].”
BackgroundBenedetti, F., Serretti, A., Colombo, C., Barbini, B., Lorenzi, C., Campori, E., & Smeraldi, E. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20038 · Cited by 324 · cited 1×
“…animal model for bipolar disorder mania is developed from deletion of exon 19 in the gene encoding for the “circadian locomotor output cycles kaput” (CLOCK) protein, which regulates circadian rhythms and is implicated in people with bipolar disorder (Benedetti et al., 2003; Serretti et al., 2003).”
BackgroundNicotinic acetylcholine receptors as targets for antidepressants
Shytle, R. D., Silver, A. A., Lukas, R. J., Newman, M. B., Sheehan, D. V., & Sanberg, P. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001035 · Cited by 279
Ralph, R. J., Paulus, M. P., Fumagalli, F., Caron, M. G., & Geyer, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00305.2001 · Cited by 271 · cited 1×
“Dopamine transporter knockout mice were hyperactive (Giros et al., 1996) and exhibited PPI deficits (Ralph et al., 2001), which were reversed by treatment with the atypical antipsychotics clozapine and olanzapine (Powell et al., 2008).”
BackgroundSelf-citationSerretti, A., Benedetti, F., Mandelli, L., Lorenzi, C., Pirovano, A., Colombo, C., & Smeraldi, E. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20053 · Cited by 264
Fusar-Poli, P., Rubia, K., Rossi, G., Sartori, G., & Balottin, U. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11060940 · Cited by 260 · cited 2×
“…striatal levels of dopamine transporter were observed in unmedicated depressed and euthymic bipolar disorder patients (Anand et al., 2011), in the postmortem tissue of bipolar disorder patients (Rao et al., 2012), but also in patients with attention deficit disorder (Fusar-Poli et al., 2012).”
BackgroundDrevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241 · cited 2×
“Intravenously administered scopolamine rapidly attenuated symptoms of depression in both major depressive disorder and bipolar depressed patients (Furey and Drevets, 2006), a finding replicated in patients with major depressive disorder (Drevets and Furey, 2010; Furey et al., 2010) and bipolar disorder depression (Fra…”
ResultIn Vivo D2 Dopamine Receptor Density in Psychotic and Nonpsychotic Patients With Bipolar Disorder
Pearlson, G. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180057008 · Cited by 235 · cited 3×
“, 2002), although increased caudate D2 receptor density was observed in psychotic bipolar disorder patients compared to healthy individuals (Pearlson et al., 1995; Wong et al., 1997).”
BackgroundJanowsky, D. S., El-Yousef, K. M., & Davis, J. M. (1974) · Psychosomatic Medicine · doi:10.1097/00006842-197405000-00008 · Cited by 230
Self-citationBrain SPECT Imaging of Amphetamine-Induced Dopamine Release in Euthymic Bipolar Disorder Patients
Anand, A., Verhoeff, P., Seneca, N., Zoghbi, S. S., Seibyl, J. P., Charney, D. S., & Innis, R. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1108 · Cited by 222
D1 dopamine receptor binding in mood disorders measured by positron emission tomography
Suhara, T., Nakayama, K., Inoue, O., Fukuda, H., Shimizu, M., Mori, A., & Tateno, Y. (1992) · Psychopharmacology · doi:10.1007/bf02253582 · Cited by 163 · cited 2×
“For instance, lower D1 receptors were observed in the frontal cortex, but not the striatum, of bipolar disorder subjects across all states compared with healthy controls (Suhara et al., 1992).”
BackgroundPinsonneault, J. K., Han, D. D., Burdick, K. E., Kataki, M., Bertolino, A., Malhotra, A. K., Gu, H. H., & Sadee, W. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.45 · Cited by 147 · cited 3×
“…of the dopamine transporter gene have been linked to bipolar disorder on numerous occasions (Greenwood et al., 2001; Greenwood et al., 2006; Pinsonneault et al., 2011) with a possible locus for bipolar disorder observed near the dopamine transporter on chromosome 5 (Kelsoe et al., 1996).”
BackgroundCharles, H. C., Lazeyras, F., Krishnan, K. R. R., Boyko, O. B., Payne, M., & Moore, D. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90115-5 · Cited by 145 · cited 2×
“…in MDD (postmortem) Gibbons et al. 2009 ↓ β2-nAChR in MDD Saricicek et al. 2012 ↓ β2-nAChR in BD depression, but not euthymic Hannestad et al. 2013 ↑ choline in MDD Charles et al. 1994; Steingard et al. 2000 Neuropharmacological Antidepressant effects of scopolamine Janowsky DS.…”
BackgroundAnand, A., Barkay, G., Dzemidzic, M., Albrecht, D., Karne, H., Zheng, Q.-H., Hutchins, G. D., Normandin, M. D., & Yoder, K. K. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00936.x · Cited by 139
Scopolamine produces larger antidepressant and antianxiety effects in women than in men
Furey, M. L., Khanna, A., Hoffman, E. M., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.131 · Cited by 138 · cited 3×
“Intravenously administered scopolamine rapidly attenuated symptoms of depression in both major depressive disorder and bipolar depressed patients (Furey and Drevets, 2006), a finding replicated in patients with major depressive disorder (Drevets and Furey, 2010; Furey et al., 2010) and bipolar disorder depression (Fra…”
BackgroundResultMineur, Y. S., Somenzi, O., & Picciotto, M. R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.01.006 · Cited by 137
Rabenstein, R. L., Caldarone, B. J., & Picciotto, M. R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0568-z · Cited by 129
George, T. P., Sacco, K. A., Vessicchio, J. C., Weinberger, A. H., & Shytle, R. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b49e · Cited by 128 · cited 2×
“…effects of scopolamine as adjuvant with SSRI in MDD Khajavi et al. 2012 Antidepressant effects of nAChR antagonist mecamylamine as adjuvant with SSRI George et al. 2008 Mood stabilizing effect of nAChR antagonist mecamylamine in BD Shytle et al. 2000 Antidepressant effects of nAChR…”
BackgroundCoque, L., Mukherjee, S., Cao, J.-L., Spencer, S., Marvin, M., Falcon, E., Sidor, M. M., Birnbaum, S. G., Graham, A., Neve, R. L., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.33 · Cited by 120 · cited 1×
“Interestingly, their mania-like behavior and disrupted circadian rhythms may be mediated by increased dopamine firing in the ventral tegmental area (Coque et al., 2011) or relate to increased dopamine release and turnover in the striatum (Spencer et al., 2012).”
BackgroundWong, D. F., Pearlson, G. D., Tune, L. E., Young, L. T., Meltzer, C. C., Dannals, R. F., Ravert, H. T., Reith, J., Kuhar, M. J., & Gjedde, A. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199703000-00010 · Cited by 118 · cited 5×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Table 2 Summary of human findings on the catecholaminergic system in mania Evidence Observations References Neuroimaging ↓ D1 receptors in BD across states Suhara et al. 1992 ≈ D2 receptors in non-psychotic BD Anand et al. 2000; Yatham et…”
BackgroundInfluentialPersistent β 2 *-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder
Saricicek, A., Esterlis, I., Maloney, K. H., Mineur, Y. S., Ruf, B. M., Muralidharan, A., Chen, J. I., Cosgrove, K. P., Kerestes, R., Ghose, S., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11101546 · Cited by 118 · cited 2×
“…M2/M4 in BD (postmortem) Zavitsanou et al. 2005 ↓ M2/M3 in BD (postmortem) Gibbons et al. 2009 ↓ M2 in MDD (postmortem) Gibbons et al. 2009 ↓ β2-nAChR in MDD Saricicek et al. 2012 ↓ β2-nAChR in BD depression, but not euthymic Hannestad et al. 2013 ↑ choline in MDD Charles et al. 1994; Steingard…”
BackgroundPhysostigmine induction of depressive symptomatology in normal human subjects
Risch, S. C., Cohen, R. M., Janowsky, D. S., Kalin, N. H., Sitaram, N., Christian Gillin, J., & Murphy, D. L. (1981) · Psychiatry Research · doi:10.1016/0165-1781(81)90012-3 · Cited by 113
Self-citationGatto, G. J., Bohme, G. A., Caldwell, W. S., Letchworth, S. R., Traina, V. M., Obinu, M. C., Laville, M., Reibaud, M., Pradier, L., Dunbar, G., et al. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00010.x · Cited by 111 · cited 2×
“…reduced symptoms of depression as an augmentation strategy with SSRI treatment (George et al., 2008) and stabilized mood in bipolar patients (Shytle et al., 2000), while antidepressant effects with nicotinic receptor agonists have also been described (Gatto et al., 2004; Dagyte et al., 2011).”
BackgroundAndreasen, J., Olsen, G., Wiborg, O., & Redrobe, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108091587 · Cited by 101 · cited 7×
“Another study suggested that nicotinic receptor antagonists, but not agonists, induced antidepressant-like effects in mice in the forced swim and tail suspension tests (Andreasen et al., 2009).”
BackgroundInfluentialDer-Avakian, A., D'Souza, M. S., Pizzagalli, D. A., & Markou, A. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.74 · Cited by 100
Rollema, H., Guanowsky, V., Mineur, Y. S., Shrikhande, A., Coe, J. W., Seymour, P. A., & Picciotto, M. R. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.01.002 · Cited by 87
Ferguson, S. M., Brodkin, J. D., Kenneth Lloyd, G., & Menzaghi, F. (2000) · Psychopharmacology · doi:10.1007/s002130000531 · Cited by 85
Amsterdam, J. D., & Newberg, A. B. (2007) · Neuropsychobiology · doi:10.1159/000106476 · Cited by 84 · cited 1×
“Higher striatal dopamine transporter binding was observed in both depressed (Amsterdam and Newberg, 2007) and drug-free euthymic (Chang et al., 2010) bipolar disorder patients.”
BackgroundReverse translational strategies for developing animal models of bipolar disorder
Malkesman, O., Austin, D. R., Chen, G., & Manji, H. K. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.001628 · Cited by 70 · cited 1×
“Combining such environmental approaches with potential genetic susceptibility relevant to bipolar disorder could be helpful in elucidating the mechanism(s) underlying the switch between depression and mania neurobiology (Malkesman et al., 2009).”
BackgroundHannestad, J. O., Cosgrove, K. P., DellaGioia, N. F., Perkins, E., Bois, F., Bhagwagar, Z., Seibyl, J. P., McClure-Begley, T. D., Picciotto, M. R., & Esterlis, I. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.004 · Cited by 63 · cited 2×
“…Gibbons et al. 2009 ↓ M2 in MDD (postmortem) Gibbons et al. 2009 ↓ β2-nAChR in MDD Saricicek et al. 2012 ↓ β2-nAChR in BD depression, but not euthymic Hannestad et al. 2013 ↑ choline in MDD Charles et al. 1994; Steingard et al. 2000 Neuropharmacological Antidepressant effects of…”
BackgroundResultChang, T. T., Yeh, T. L., Chiu, N. T., Chen, P. S., Huang, H. Y., Yang, Y. K., Lee, I. H., & Lu, R. B. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00771.x · Cited by 63
Powell, S. B., Young, J. W., Ong, J. C., Caron, M. G., & Geyer, M. A. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830dc110 · Cited by 57 · cited 2×
“…aripiprazole ↓ stimulant-induced hyperactivity Antimania-like Mavrikaki et al. 2010 Antipsychotics clozapine and olanzapine ↓ PPI deficits of DAT knockout mice Antimania-like Powell et al. 2008 AMPT ↓ some behavioral deficits of DAT mouse models Antimania-like Van Enkhuizen et al. 2014 DA =…”
BackgroundSelf-citationEffect of lithium on the physostigmine-induced behavioral syndrome and plasma cyclic GMP
Oppenheim, G., Ebstein, R. P., & Belmaker, R. H. (1979) · Journal of Psychiatric Research · doi:10.1016/0022-3956(79)90024-4 · Cited by 48 · cited 2×
“, 1964), including physostigmine (Janowsky et al., 1973b; Modestin et al., 1973b, 1973a; Janowsky et al., 1974; Davis et al., 1978; Oppenheim et al., 1979; Risch et al., 1981) have been reported to induce symptoms of depression in human subjects.”
BackgroundAndreasen, J. T., Henningsen, K., Bate, S., Christiansen, S., & Wiborg, O. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391831 · Cited by 46 · cited 9×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Table 3 Summary of cholinergic findings from animal studies and depression-like behavior Manipulation Observations Interpretation References Nicotinic α7-nAChR agonist ↓ immobility in mice Antidepressant-like Andreasen et al. 2012 Subtype-…”
BackgroundInfluentialAndreasen, J. T., Redrobe, J. P., & Nielsen, E. Ø. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.11.004 · Cited by 43 · cited 6×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Table 3 Summary of cholinergic findings from animal studies and depression-like behavior Manipulation Observations Interpretation References Nicotinic α7-nAChR agonist ↓ immobility in mice Antidepressant-like Andreasen et al. 2012 Subtype-…”
BackgroundInfluentialShytle, R. D., Silver, A. A., & Sanberg, P. R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00945-8 · Cited by 41
Cited by
The Inositol Trisphosphate/Calcium Signaling Pathway in Health and Disease
Berridge, M. J. (2016) · Physiological Reviews · doi:10.1152/physrev.00006.2016 · Cited by 753
Walczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics
Dulawa, S. C., & Janowsky, D. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0219-x · Cited by 187
Self-citationMice with reduced DAT levels recreate seasonal-induced switching between states in bipolar disorder
Young, J. W., Cope, Z. A., Romoli, B., Schrurs, E., Joosen, A., van Enkhuizen, J., Sharp, R. F., & Dulcis, D. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0031-y · Cited by 81
“Research to-date has provided insights into the underlying neurochemistry during periods of depression and mania, identifying altered cholinergic-mediated and dopaminergic-mediated function among the factors that influence these two states respectively [6].”
BackgroundSelf-citationThe role of acetylcholine in negative encoding bias: Too much of a good thing?
Mineur, Y. S., & Picciotto, M. R. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14641 · Cited by 78
Metadata
- Authors
- van Enkhuizen, J., Janowsky, D. S., Olivier, B., Minassian, A., Perry, W., Young, J. W., & Geyer, M. A.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 753
- Pages
- 114-126
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W2050678707
- Cited by
- 105
- References
- 52
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.